Galapagos NV is based in Mechelen, Belgium, and Gilead Therapeutics holds subscription rights for Galapagos shares.
3 reports, 2 independent
Updated Aug 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Galapagos NV is based in Mechelen, Belgium, and Gilead Therapeutics holds subscription rights for Galapagos shares.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Gilead Therapeutics holds subscription rights for shares of Galapagos NV, which is based in Belgium.1 source
FDA granted RMAT designation to Galapagos's product.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- GlobeNewswireGalapagos Creates New Subscription Right Plan Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors
- GlobeNewswireGalapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma Mechelen, Belgium; August 6
- Simply Wall St.Galapagos Second Quarter 2025 Earnings: Misses Expectations Revenue: €65.3m (down 16% from 2Q 2024). Net loss: €104.5m (down from €4.66m profit in 2Q 2024). €1.58 loss per share (down from €0.071 pro